| Pharmaceutical Information |
| Drug Name |
Elosulfase alfa |
| Drug ID |
BADD_D00758 |
| Description |
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. |
| Indications and Usage |
Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). |
| Marketing Status |
Prescription |
| ATC Code |
A16AB12 |
| DrugBank ID |
DB09051
|
| KEGG ID |
D10333
|
| MeSH ID |
C102295
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0J1UA
|
| NDC Product Code |
71931-500; 68135-100 |
| Synonyms |
GALNS protein, human | N-acetylgalactosamine-6-sulfatase, human | mucopolysaccharidosis type IVA protein, human | galactose-6-sulfate sulfatase, human | GALNAC6S protein, human | Morquio syndrome protein, human | galactosamine (N-acetyl)-6-sulfate sulfatase, human | Vimizim | elosulfase alfa | BMN-100 | BMN 110 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
9025-60-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
